BRPI0621800B8 - anticorpos que se ligam à proteína fzd10, clones de hibridoma, composições farmacêuticas, kit compreendendo os referidos anticorpos, e método para diagnose ou prognose de uma doença que é associada a homólogo fzd10 ou de uma predisposição para desenvolver a doença em um indivíduo - Google Patents

anticorpos que se ligam à proteína fzd10, clones de hibridoma, composições farmacêuticas, kit compreendendo os referidos anticorpos, e método para diagnose ou prognose de uma doença que é associada a homólogo fzd10 ou de uma predisposição para desenvolver a doença em um indivíduo

Info

Publication number
BRPI0621800B8
BRPI0621800B8 BRPI0621800A BRPI0621800A BRPI0621800B8 BR PI0621800 B8 BRPI0621800 B8 BR PI0621800B8 BR PI0621800 A BRPI0621800 A BR PI0621800A BR PI0621800 A BRPI0621800 A BR PI0621800A BR PI0621800 B8 BRPI0621800 B8 BR PI0621800B8
Authority
BR
Brazil
Prior art keywords
fzd10
antibodies
disease
diagnosing
individual
Prior art date
Application number
BRPI0621800A
Other languages
English (en)
Portuguese (pt)
Inventor
Endo Keigo
Nakatsuru Shuichi
Katagiri Toyomasa
Nakamura Yusuke
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI0621800A2 publication Critical patent/BRPI0621800A2/pt
Publication of BRPI0621800B1 publication Critical patent/BRPI0621800B1/pt
Publication of BRPI0621800B8 publication Critical patent/BRPI0621800B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0621800A 2006-06-21 2006-08-24 anticorpos que se ligam à proteína fzd10, clones de hibridoma, composições farmacêuticas, kit compreendendo os referidos anticorpos, e método para diagnose ou prognose de uma doença que é associada a homólogo fzd10 ou de uma predisposição para desenvolver a doença em um indivíduo BRPI0621800B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81525706P 2006-06-21 2006-06-21
US60/815,257 2006-06-21
PCT/JP2006/317155 WO2007148417A1 (en) 2006-06-21 2006-08-24 Tumor-targeting monoclonal antibodies to fzd10 and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0621800A2 BRPI0621800A2 (pt) 2011-12-20
BRPI0621800B1 BRPI0621800B1 (pt) 2020-03-24
BRPI0621800B8 true BRPI0621800B8 (pt) 2022-01-04

Family

ID=37616924

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0621800A BRPI0621800B8 (pt) 2006-06-21 2006-08-24 anticorpos que se ligam à proteína fzd10, clones de hibridoma, composições farmacêuticas, kit compreendendo os referidos anticorpos, e método para diagnose ou prognose de uma doença que é associada a homólogo fzd10 ou de uma predisposição para desenvolver a doença em um indivíduo

Country Status (10)

Country Link
US (2) US8221751B2 (enExample)
EP (2) EP2386577A3 (enExample)
JP (1) JP5028635B2 (enExample)
KR (1) KR101351208B1 (enExample)
CN (1) CN101573383B (enExample)
BR (1) BRPI0621800B8 (enExample)
CA (1) CA2655289C (enExample)
ES (1) ES2405618T3 (enExample)
RU (1) RU2412203C2 (enExample)
WO (1) WO2007148417A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2500360B1 (en) 2005-10-31 2015-08-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2668714A1 (en) * 2006-11-14 2008-05-22 Novartis Ag Methods of treating, diagnosing or detecting cancer
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
JP5407042B2 (ja) * 2009-12-16 2014-02-05 公益財団法人ヒューマンサイエンス振興財団 セセルニン−１の使用、滑膜肉腫の予後予測方法及び検査用試薬キット
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
EP2720721B1 (en) 2011-06-17 2017-08-30 President and Fellows of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
WO2013025446A2 (en) * 2011-08-12 2013-02-21 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
USRE49477E1 (en) 2012-04-20 2023-03-28 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
JP6796059B2 (ja) 2014-09-12 2020-12-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｗｎｔシグナリングアゴニスト分子
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
JP6829469B2 (ja) * 2015-08-10 2021-02-10 国立大学法人富山大学 抗原特異的モノクローナル抗体作製方法
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
CN113082201B (zh) * 2016-04-01 2024-07-05 上海斯丹赛生物技术有限公司 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
TWI762516B (zh) * 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對ｆｚｄ１０之單株抗體及其用途
JP7617603B2 (ja) 2017-01-11 2025-01-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｒ－スポンジン（ｒｓｐｏ）サロゲート分子
AU2018211985B2 (en) 2017-01-26 2025-02-13 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
JP7418332B2 (ja) 2017-12-19 2024-01-19 スロゼン オペレーティング， インコーポレイテッド 抗フリズルド抗体及び使用方法
CN118271444A (zh) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
AU2019297522B2 (en) 2018-07-05 2026-04-23 Surrozen Operating, Inc. Multi-specific Wnt surrogate molecules and uses thereof
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
WO2022104280A1 (en) 2020-11-16 2022-05-19 Surrozen Operating, Inc. Liver-specific wnt signal enhancing molecules and uses thereof
CN115724977B (zh) * 2022-11-04 2025-06-13 中国科学技术大学 针对人卷曲受体的单克隆抗体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
GB9414580D0 (en) 1994-07-19 1994-09-07 Cancer Res Campaign Tech Materials and methods relating to the diagnosis of synovial sarcomas
US5994098A (en) * 1997-06-02 1999-11-30 Smithkline Beecham Corporation Human 7-TM receptor similar to murine frizzled-6 gene
EP0943684A3 (en) 1998-03-10 2002-01-23 Smithkline Beecham Plc Frizzled-like polypeptides and polynucleotides
GB9819681D0 (en) 1998-09-09 1998-11-04 Smithkline Beecham Plc Novel compounds
WO2001074405A1 (en) 2000-03-31 2001-10-11 Gene Logic, Inc. Gene expression profiles in esophageal tissue
CA2456008A1 (en) 2000-08-19 2002-02-28 Axordia Limited Stem cell differentiation
US6964849B2 (en) * 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
EP1358327A2 (en) 2001-01-11 2003-11-05 Curagen Corporation Proteins and nucleic acids encoding same
CA2444691A1 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002308557A1 (en) 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20030044409A1 (en) * 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
WO2003004045A2 (en) 2001-07-05 2003-01-16 Xenon Genetics, Inc. Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
AU2003256079A1 (en) 2002-08-30 2004-03-19 Japan As Represented By President Of The University Of Tokyo Method for treating synovial sarcoma
EP1549144A4 (en) 2002-10-04 2010-01-06 Univ California METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE
JP4691626B2 (ja) * 2003-07-11 2011-06-01 オンコセラピー・サイエンス株式会社 滑膜肉腫の治療方法
EP1789549A1 (en) 2004-08-05 2007-05-30 The University of Tokyo Method for treating synovial sarcoma using sirna for fzd10

Also Published As

Publication number Publication date
US20130230521A1 (en) 2013-09-05
US20110044896A1 (en) 2011-02-24
JP5028635B2 (ja) 2012-09-19
EP2044123A1 (en) 2009-04-08
CN101573383A (zh) 2009-11-04
EP2386577A2 (en) 2011-11-16
JP2009541204A (ja) 2009-11-26
CA2655289A1 (en) 2007-12-27
EP2044123B1 (en) 2013-03-13
WO2007148417A1 (en) 2007-12-27
CA2655289C (en) 2016-08-23
KR20090029275A (ko) 2009-03-20
EP2386577A9 (en) 2011-12-28
CN101573383B (zh) 2015-05-13
RU2412203C2 (ru) 2011-02-20
US9139655B2 (en) 2015-09-22
BRPI0621800B1 (pt) 2020-03-24
US8221751B2 (en) 2012-07-17
RU2009101788A (ru) 2010-08-10
EP2386577A3 (en) 2012-05-02
BRPI0621800A2 (pt) 2011-12-20
ES2405618T3 (es) 2013-05-31
KR101351208B1 (ko) 2014-01-14

Similar Documents

Publication Publication Date Title
BR112012007365A2 (pt) proteínas de ligação à il-1
CL2021003327A1 (es) Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089).
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
EP2386577A3 (en) Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
CN111051345A (zh) 柄蛋白-4结合蛋白及其使用方法
BR112014018481A2 (pt) anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
MX2012004084A (es) Anticuerpos siglec-15 para tratar enfermedad relacionada con perdida osea.
BRPI0710645A2 (pt) Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
BRPI0513890A (pt) anticorpo, hibridoma murino, composição, uso dos mesmos, e, método de diagnóstico in vitro de doenças
BR112013011065A2 (pt) "anticorpo anti-il-23p19 ou seu fragmento de ligação ao antígeno, composição farmacêutica, uso de um anticorpo ou do fragmento de ligação, método para inibir a ligação da il-23 para o receptor da il-23 em uma célula de mamífero, polinucleotídeo isolado e kit"
ECSP099658A (es) Anticuerpos anti-esclerostina
CA2621363C (en) Methods and compositions for modulating tumor cell activity
BRPI0808940B8 (pt) anticorpo humano-murino quimérico ou xegogeneico, humanizado, humano ou seu fragmento de ligação, vetor de expressão, microrganismo transgênico, método para preparar um anticorpo ou um fragmento de ligação, composição, composição de diagnóstico, uso do anticorpo ou fragmento de ligação, kit para o diagnóstico de um tumor e uso da molécula de antígeno ligante ao tumor
HRP20131113T1 (hr) Protutijela protiv erbb3 i njihova uporaba
CN109219615A (zh) 识别tau的抗体
BRPI0717363B8 (pt) imunoglobina humanizada que liga especificamente cd20, composição, vetor recombinante, métodos para obter uma célula hospedeira, de produção de uma imunoglobina que liga especificamente cd20, in viro para inibir o crescimento ou diferenciação de uma célula b humana normal e usos de imunoglobina e de uma quantidade efetiva de imunoglobina
RU2017145653A (ru) Средства, пути применения и способы лечения синуклеопатии
BR112015007882A2 (pt) anticorpo monoclonal isolado que se liga a alfa sinucleína humana, ácido nucleico, composição farmacêutica e uso do anticorpo
MX2013008833A (es) Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
PE20090368A1 (es) Anticuerpos anti-igf
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
RU2012136113A (ru) Ингибирование axl сигнализации в антиметастатической терапии
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
WO2009048539A3 (en) Use of anti-amyloid beta antibody in ocular diseases

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/08/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2568 DE 24/03/2020 QUANTO AOS INVENTORES.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2846 DE 22-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.